Contact Dermatitis (CD) - Market Insights, Epidemiology and Market Forecast– 2030

DelveInsight’s ‘Contact Dermatitis (CD) - Market Insights, Epidemiology and Market Forecast– 2030’ report delivers an in-depth understanding of the Contact Dermatitis (CD), historical and forecasted epidemiology as well as the Contact Dermatitis (CD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Contact Dermatitis (CD) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Contact Dermatitis (CD) market size from 2017 to 2030. The report also covers current Contact Dermatitis (CD) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2017–2030
Contact Dermatitis (CD) Disease Understanding and Treatment Algorithm
Contact Dermatitis (CD) Overview
Contact dermatitis (CD) is a type of eczema triggered by contact with a particular substance in the environment that the person is allergic to, it may react by causing the skin to itch and become red. Eczema is the name for a group of conditions that cause skin to become dry and irritated. CD usually improves or clears up completely if the substance causing the problem is identified and avoided. Treatments are also available to help ease the symptoms.

CD is a common inflammatory skin condition characterized by erythematous and pruritic skin lesions that occur after contact with a foreign substance. The most common substances that cause CD include poison ivy, nickel, and fragrances. CD usually leads to erythema and scaling with visible borders. Itching and discomfort may also occur.
Clinical symptoms depend primarily on whether the dermatitis is acute or chronic, as well as on the toxin involved, type of contact, pathomechanism, and localization, among other factors. Although all types of dermatitis generally share common features, the classic eczematous stages in CD are most readily identifiable.

Acute CD is characterized by pathological symptoms over the entire lesion:
• Mild form: erythema at the site of exposure to the toxin, contact traces, and itching are possible.
• Severe form: ranging from vesicular papules to blisters, usually causing strong itching. A feeling of tightness of the skin and even pain may occur. Blister rupture is followed by weeping, scab formation, and later by scaliness. Spreading reactions are possible in the case of an allergic trigger.

CD is a common skin problem occurring in 15–20% of people. Irritant Contact Dermatitis (ICD) is more common (80%) and can occur in anyone, especially after repeated exposure. Allergic contact dermatitis (ACD), on the other hand, is seen in genetically predisposed and previously sensitized individuals who react to even low concentrations of the agent. Cosmetics, medicines, clothes dyes, as well as foods, rubber and poison ivy are common causes of ACD. Any topical cream or ointment may contain chemicals that irritate the skin.

Contact Dermatitis (CD) Diagnosis
The diagnosis of CD is most often made with history and physical examination findings. Irritant and allergic CD may be complicated by bacterial superinfection, and bacterial culture should be considered with the presence of exudate, weeping, and crusting. A potassium hydroxide (KOH) preparation is useful if tinea or Candida infection is suspected, because these fungal infections can have erythema and scaling similar to contact dermatitis. If the KOH preparation has negative results but a fungal etiology is still suspected, a fungal culture should be sent for laboratory testing. Dermoscopy and microscopy can be used to look for scabies and mites.

When a possible causative substance is known, the first step in confirming the diagnosis is observing whether the problem resolves with avoidance of the substance. If avoidance and empiric treatment do not resolve the dermatitis or the allergen remains unknown, patch testing may be indicated. In one study, patch testing had a sensitivity and specificity of between 70–80%. However, it is expensive and time-consuming, and prohibits the patient from showering (a “sponge bath” technique may be used). Patch testing should not be confused with other types of allergy testing. Skin prick and radio-allergosorbent tests are used for the diagnosis of type I hypersensitivity, such as respiratory, latex, and food allergies, but not for contact dermatitis.

In some cases, a repeated open application test (ROAT) is useful, particularly to assess cosmetics. A ROAT involves reapplying the substance onto the same area of skin twice a day for 7 days, to see how the patients’ skin reacts. This is a particularly useful way for anyone to check their cosmetics at home for reactions.
Contact Dermatitis (CD) Treatment
In patients with contact dermatitis, the priority is to identify and avoid the causative substance. Cool compresses can soothe the symptoms of acute contact dermatitis, and calamine lotion and colloidal oatmeal baths may help dry and soothe acute, oozing lesions.

Localized acute allergic CD lesions are successfully treated with mid- or high-potency topical steroids, such as triamcinolone 0.1% (Kenalog, Aristocort) or clobetasol 0.05% (Temovate). On areas with thinner skin (e.g., flexural surfaces, eyelids, face, anogenital region), lower-potency steroids, such as desonide ointment (Desowen), can be helpful and minimize the risk of skin atrophy. There are insufficient data to support the use of topical steroids for irritant contact dermatitis. However, because it is difficult to clinically distinguish between allergic and irritant contact dermatitis, these agents are often used successfully for the irritant form as well.

Till date, there is no approved therapy specific for CD. The treatment paradigm is mostly similar to that of Atopic Dermatitis. Therefore, the current treatment of CD is mainly dominated by the use of off-label therapies, which includes Topical Corticosteroids (Clobetasol and Triamcinolone) and Emollients, Topical Immunosupressants (Pimecromilus and Tacrolimus), Systemic Immunosupressants (Antihistamines) and Corticosteroids and Others (Antiseptics, Topical Antibiotics, Phototherapy and Other Immunosupressants).

Contact Dermatitis (CD) Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Population of Contact Dermatitis, Type-specific Diagnosed Prevalent Population of Contact Dermatitis Based on Clinical and Biological Evolution, Gender-specific Diagnosed Prevalent Population of Contact Dermatitis, Age-specific Diagnosed Prevalent Population of Contact Dermatitis and Type-specific Diagnosed Prevalent Population of Contact Dermatitis in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.

Key Findings
This section provides glimpse of the Contact Dermatitis (CD) epidemiology in the 7MM.
• The total diagnosed prevalent population of CD in the 7 major markets was found to be 43,359,201 in 2017.
• In case of CD in the United States, the diagnosed prevalent cases were found to be 13,786,942 in 2017.
• It was found that in the United States the number of cases of ICD and ACD were 11,029,554 and 2,757,388 respectively in 2017.
• In addition, the number of cases of acute, sub-acute and chronic type of CD were 7,611,771, 2,903,530 and 3,271,641 respectively in 2017, in the United States.
• Gender-specific data of the United States suggests that the number of cases of CD in males and females were 4,825,430 and 8,961,513 respectively in 2017.
• Age-specific data for CD suggests that in the United States the maximum number of cases of CD were found in the age group of 46–60 with 4,411,822 cases in 2017, while the lowest number of cases were found in the age group 75+ with 275,739 cases in 2017.
• In the EU5 countries, the diagnosed prevalence of CD was found to be maximum in Germany with 6,645,210 cases, followed by France with 5,481,080 cases in 2017. While, the least number of cases were found in Spain, with 1,982,709 cases in 2017.
• In Japan, the diagnosed prevalence of CD was found to be 5,107,575 in 2017.

Country Wise- Contact Dermatitis (CD) Epidemiology
The epidemiology segment also provides the Contact Dermatitis (CD) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Contact Dermatitis (CD) Drug Chapters
The drug chapter segment of the Contact Dermatitis (CD) report encloses the detailed analysis of Contact Dermatitis (CD) marketed drugs and mid and late stage pipeline drugs. It also helps to understand the Contact Dermatitis (CD) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug and the latest news and press releases.

Contact Dermatitis (CD) Emerging Drugs
EB01 Cream: Edesa Biotech
EB01 is a novel sPLA2 inhibitor for the topical treatment of chronic ACD. The sPLA2 inhibitors are designed to inhibit the inflammatory process at its inception rather than after inflammation has occurred. The drug inhibits sPLA2 from degrading phospholipids to produce arachidonic acid. Arachidonic acid is processed via the LOX-COX pathway to generate several pro-inflammatory signalling molecules. The drug exerts its anti-inflammatory activity upstream of currently approved NSAIDs, which target the LOX-COX pathway. The FDA accepted Edesa’s investigational new drug (IND) application of EB01 for CD patients in November 2018. In June 2019, Edesa Biotech and Stellar Biotechnologies completed share exchange agreement. The combined company, called Edesa Biotech, thereafter, focused on the development and advancement of innovative treatments for dermatological and gastrointestinal indications. In December 2019, the company reported that EB01 had demonstrated positive safety data in healthy volunteers participating in its ongoing phase IIb clinical study in chronic ACD. Considering this positive result, the company expanded the phase IIb dermatitis study to patients with facial lesions. Currently, the drug is still being investigated in phase II clinical developmental trial in the United States for CD.

Product detail in the report…
PDC-APB: Hapten Sciences
PDC-APB is a small molecule that acts like a vaccine to prevent the excruciating itching and rash (CD) caused by exposure to urushiol (yoo-ROO-she-ol) oil in poison ivy, poison oak, and poison sumac plants. Hapten licensed PDC-APB from the University of Mississippi in 2010. In 2015, the company had filed an Investigational New Drug (IND) application of PDC-APB for CD caused by poison ivy, poison oak, and poison sumac plants. The drug has already completed its phase I trial in January 2018 and in June 2019, Hapten Sciences published data regarding attainment of a fourth patent by the University of Mississippi for its investigational product that could prevent the painful itching and rash due to exposure to poison ivy, poison oak, and poison sumac.

Product detail in the report…
Contact Dermatitis (CD) Market Outlook
According to the American Academy of Allergy Asthma and Immunology (AAAAI), the CD is a common skin problem that occurs in ~15–20% of people. It can pose a significant financial burden with direct and indirect costs from lost time off work and school. CD can either be of allergic (ACD) type or irritant (ICD) type. Out of these two, ICD is more common (80%) and can occur in anyone, especially after repeated exposure. Additionally, in 2004, the Society of Investigative Dermatology revealed that ~72.3 million people were suffering from CD in the United States, representing one of the top five most economically burdensome skin diseases.

Since there are no approved therapies for CD, the market is mainly dominated by the use of off-label prescription drugs. Treatments for CD include Topical Corticosteroids (Clobetasol and Triamcinolone) and Emollients, Topical Immunosupressants (Pimecromilus and Tacrolimus), Systemic Immunosupressants (Antihistamines) and Corticosteroids, and Others (Antiseptics, Topical Antibiotics, Phototherapy, and Other Immunosupressants). However, topical corticosteroids remain the mainstay or the first-line treatment option for CD while phototherapy and systemic immune modulators form the second-line treatment option for the indication.

The American Academy of Allergy, Asthma, and Immunology (AAAAI) has published separate diagnostic and management guidelines for both CD and atopic dermatitis (AD). As per these guidelines, the treatment pattern of both the indications was quite similar. Even though the pathophysiology of AD and CD are extremely different as AD is an immunodeficiency disorder and CD is contact triggered disorder, but the signs and symptoms of both the diseases are quite similar that justifies the same prescription pattern as well. Keeping this in mind, the US CD market forecast considers AD prescription pattern.

However, the current emerging market of CD does not possess a robust pipeline. There is only one therapy, EB01 Cream, which is in its phase II developmental stage. Additionally, there is another therapy, namely, PDC-APB that has completed its phase I trial and was licensed by Hapten from the University of Mississippi in 2010. The phase I trial of PDC-APB was completed in January 2018 itself; however, the results of this trial has not been published yet. Therefore, Hapten’s PDC-APB has not been considered in the forecast model of CD report.

Key Findings
This section includes a glimpse of the Contact Dermatitis (CD) 7MM market.
• The market size of CD in the seven major markets was estimated to be USD 7,831 Million in 2017.
• The United States accounts for the largest market size of CD, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
• Among the EU5 countries, Germany had the highest market size with USD 981 Million in 2017, while Spain had the lowest market size of CD with USD 293 Million in 2017.
• The Japan CD market accounted for USD 752 Million in 2017, which is expected to increase during the forecast period of 2020–2030.

The United States Market Outlook
This section provides the total Contact Dermatitis (CD) market size and market size by therapies in the United States.

EU-5 Market Outlook
The total aspregillosis market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook
The total Contact Dermatitis (CD) market size and market size by therapies in Japan are provided.

Contact Dermatitis (CD) Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the Contact Dermatitis (CD) market or expected to get launched in the market during the study period 2017–2030. The analysis covers Contact Dermatitis (CD) market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Contact Dermatitis (CD) Development Activities
The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing and patent details for Contact Dermatitis (CD) emerging therapies.

Competitive Intelligence Analysis
We perform competitive and market Intelligence analysis of the Contact Dermatitis (CD) market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report
• The report covers the descriptive overview of Contact Dermatitis (CD), explaining its causes, signs and symptoms, pathogenesis and currently available therapies.
• Comprehensive insight has been provided into the Contact Dermatitis (CD) epidemiology and treatment.
• Additionally, an all-inclusive account of both the current and emerging therapies for Contact Dermatitis (CD) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
• A detailed review of Contact Dermatitis (CD) market; historical and forecasted is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Contact Dermatitis (CD) market.

Report Highlights
• In the coming years, Contact Dermatitis (CD) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence Contact Dermatitis (CD) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• DelveInsight has analyzed type-based data for Contact Dermatitis (CD). Contact Dermatitis can be of two types based on this data, namely, Irritant Contact Dermatitis (ICD) and Allergic Contact Dermatitis (ACD).
• Type-specific data based on clinical and biological evolution of Contact Dermatitis (CD) has also been analyzed by Delvelnsight. On this basis, Contact Dermatitis can be divided as Acute, Sub-acute and Chronic type.
• In addition, Delvelnsight has also analyzed gender-specific data for Contact Dermatitis (CD), which clearly suggests that CD is more prevalent among females than males.
• The report also encompasses another major segment, i.e., Age-specific Diagnosed Prevalent Population of Contact Dermatitis (CD), wherein various age groups have been considered, such as 0–17, 18–29, 30–45, 46–60, 61–75 and 75+. It has been found that CD majorly affects patients whose age is 40 years or above.
• Expected Launch of a potential therapy, EB01 (Edesa Biotech), may increase the market size in the coming years, assisted by an increase in diagnosed prevalent population of Contact Dermatitis (CD).
• The current treatment of Contact Dermatitis (CD) is mainly dominated by the use of off-label therapies, which includes Topical Corticosteroids (Clobetasol and Triamcinolone) and Emollients, Topical Immunosupressants (Pimecromilus and Tacrolimus), Systemic Immunosupressants (Antihistamines) and Corticosteroids and Others (Antiseptics, Topical Antibiotics, Phototherapy and Other Immunosupressants).

Contact Dermatitis (CD) Report Insights
• Patient Population
• Therapeutic Approaches
• Contact Dermatitis (CD) Pipeline Analysis
• Contact Dermatitis (CD) Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies
Contact Dermatitis (CD) Report Key Strengths
• Eleven Years Forecast
• 7MM Coverage
• Contact Dermatitis (CD) Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake
Contact Dermatitis (CD) Report Assessment
• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Questions
Market Insights:
• What was the Contact Dermatitis (CD) market share (%) distribution in 2017 and how it would look like in 2030?
• What would be the Contact Dermatitis (CD) total market size as well as market size by therapies across the 7MM during the forecast period (2020–2030)?
• What are the key findings pertaining to the market across the 7MM and which country will have the largest Contact Dermatitis (CD) market size during the forecast period (2020–2030)?
• At what CAGR, the Contact Dermatitis (CD) market is expected to grow at the 7MM level during the forecast period (2020–2030)?
• What would be the Contact Dermatitis (CD) market outlook across the 7MM during the forecast period (2020–2030)?
• What would be the Contact Dermatitis (CD) market growth till 2030 and what will be the resultant market size in the year 2030?
• How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:
• What is the disease risk, burden and unmet needs of Contact Dermatitis (CD)?
• What is the historical Contact Dermatitis (CD) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
• What would be the forecasted patient pool of Contact Dermatitis (CD) at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Contact Dermatitis (CD)?
• Out of the above-mentioned countries, which country would have the highest prevalent population of Contact Dermatitis (CD) during the forecast period (2020–2030)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2020–2030)?
Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
• What are the current options for the treatment of Contact Dermatitis (CD) along with the approved therapy?
• What are the current treatment guidelines for the treatment of Contact Dermatitis (CD) in the US and Europe?
• What are the Contact Dermatitis (CD) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many companies are developing therapies for the treatment of Contact Dermatitis (CD)?
• How many therapies are developed by each company for the treatment of Contact Dermatitis (CD)?
• How many emerging therapies are in the mid-stage and late stage of development for the treatment of Contact Dermatitis (CD)?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Contact Dermatitis (CD) therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Contact Dermatitis (CD) and their status?
• What are the key designations that have been granted for the emerging therapies for Contact Dermatitis (CD)?
• What are the 7MM historical and forecasted market of Contact Dermatitis (CD)?

Reasons to buy
• The report will help in developing business strategies by understanding trends shaping and driving the Contact Dermatitis (CD).
• To understand the future market competition in the asprgillosis market and Insightful review of the key market drivers and barriers.
• Organize sales and marketing efforts by identifying the best opportunities for Contact Dermatitis (CD) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Organize sales and marketing efforts by identifying the best opportunities for Contact Dermatitis (CD) market.
• To understand the future market competition in the Contact Dermatitis (CD) market.